Sure.
I've heard the arguments and concerns of pharmaceutical about lower prices. My understanding of those arguments is that, to the extent that prices are lower in Canada than they are today, maybe that wouldn't attract the same level of investment from abroad, or the establishment or maintenance of head offices here in Canada. That's my understanding of their concern.
From the perspective I was speaking to, we have amongst the highest prices in the world for pharmaceuticals. We have scarce resources. We have concerns about Canadians and other payers being able to afford the medicines they need. I think it's critical that we have lower-priced medicines, which the changes to the PMPRB would achieve. Even to have them at the median price levels amongst the G7, for example, would bring them down dramatically and the reduce the effects on Canadians.
I haven't seen what evidence might exist of the impact of that on investment or the pharmaceutical offices maintaining headquarters here. I can't speak to that. I haven't seen.
Those are sort of the two sides of the perspective. I hope that addresses your question.